论文部分内容阅读
目的探讨Toll样受体4(TLR4)、P-糖蛋白(P-gp)在卵巢上皮癌组织中的表达及其临床意义。方法采用免疫组化SP法,检测50例卵巢上皮癌(化疗敏感组25例,化疗耐药组25例)组织和10例正常卵巢组织中TLR4、P-gp的表达。结果卵巢上皮癌组织中TLR4和P-gp的阳性表达率分别为62%和46%,明显高于正常卵巢组织的20%和10%(χ2=5.939、4.500,P<0.05)。卵巢上皮癌化疗耐药组TLR4和P-gp阳性表达率明显高于化疗敏感组(χ2=6.876、6.522,P<0.05)。卵巢上皮癌组织TLR4的表达与病理分级、临床分期和淋巴结转移有相关性(χ2=6.848、6.376、5.433,P<0.05),P-gp表达与病理分级、淋巴结转移具有相关性(χ2=9.071、6.402,P<0.05);TLR4、P-gp蛋白表达具有正相关性(r=0.392,P<0.05)。结论 TLR4和P-gp的高表达及其相关性与卵巢上皮癌的化疗耐药及预后关系密切。
Objective To investigate the expression of Toll-like receptor 4 (TLR4) and P-glycoprotein (P-gp) in epithelial ovarian cancer and its clinical significance. Methods Immunohistochemical SP method was used to detect the expression of TLR4 and P-gp in 50 cases of epithelial ovarian cancer (25 cases of chemosensitive group, 25 cases of chemoresistant group) and 10 cases of normal ovarian tissue. Results The positive rates of TLR4 and P-gp in epithelial ovarian cancer tissues were 62% and 46%, respectively, which were significantly higher than those in normal ovarian tissues (χ2 = 5.939, 4.500, P <0.05). The positive rates of TLR4 and P-gp in chemotherapy-resistant group were significantly higher than those in chemotherapy-sensitive group (χ2 = 6.876,6.522, P <0.05). The expression of TLR4 in ovarian epithelial carcinoma was correlated with pathological grade, clinical stage and lymph node metastasis (χ2 = 6.848,6.376,5.433, P <0.05). The expression of P-gp was correlated with pathological grade and lymph node metastasis (χ2 = 9.071 , 6.402, P <0.05). There was a positive correlation between TLR4 and P-gp protein expression (r = 0.392, P <0.05). Conclusion The high expression of TLR4 and P-gp and their correlation with chemotherapy resistance and prognosis of epithelial ovarian cancer are closely related.